lung cancer

Roche lung cancer drug cuts death risk 44% vs rivals

Roche's experimental drug divarasib helped patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC) live longer than the two approved drugs in its class. In the Phase III Krascendo 1 trial, it lowered the risk of death by…

Amgen’s Imdelltra combo cuts lung cancer death risk 58%

Adding Amgen's Imdelltra (tarlatamab) to AstraZeneca's Imfinzi (durvalumab) cut the risk of death by 58% compared with Imfinzi alone in patients with extensive-stage small cell lung cancer, according to Phase 3 data presented on Saturday, October 24, at a major…

  • 2 mins

Vatican says Pope Leo needs no further cancer treatment

Pope Leo XIV will not need chemotherapy or any other further treatment after surgeons removed a cancerous tumor from his right lung, his doctors said in a statement the Vatican released on Wednesday, Oct. 21. "The final histological reports and…

  • 2 mins

Pope Leo walking, eating normally after lung cancer surgery

Pope Leo XIV is walking in his hospital room, eating normal meals and doing breathing exercises one day after surgeons removed part of his right lung to treat cancer, the Vatican said Wednesday. His doctors said his recovery "is proceeding…

  • 3 mins

Vatican says Pope Leo XIV has lung cancer after surgery

Pope Leo XIV has lung cancer, the Vatican said Tuesday. During surgery at Rome's Gemelli hospital, doctors removed the lower lobe of his right lung, and a medical bulletin confirmed a diagnosis of lung adenocarcinoma, a common form of the…

Rare gene mutation raises lung cancer risk 60-fold in nonsmokers, study finds

A rare inherited mutation in the EGFR gene is associated with a 25-fold increased risk of lung cancer — and among people who have never smoked, the risk jumps to more than 60-fold — according to a study published Thursday…

GSK’s lung cancer drug shows 94% response rate in frontline trial

GSK presented data on Monday at the 2026 World Conference on Lung Cancer in Seoul showing that its ROS1 inhibitor Jideytro, known generically as zidesamtinib, produced a 94% objective response rate in patients with advanced ROS1-positive non-small cell lung cancer…

GSK lung cancer drug cuts death risk by 54% in pivotal trial

GSK reported on Sunday that its cancer drug risvutatug rezetecan, known as Ris-Rez, reduced the risk of death by 54% compared with standard treatment in patients with relapsed small cell lung cancer, results that sent the company's shares higher at…

BioNTech drug nearly doubles survival in lung cancer

BioNTech and its partner OncoC4 on Monday presented updated data showing that their experimental drug gotistobart nearly doubled median overall survival in patients with pretreated squamous non-small cell lung cancer, a disease with few effective treatment options after initial therapy…

Immunotherapy nearly doubles survival time in early-stage lung cancer trial

Adding the immunotherapy drug atezolizumab to chemotherapy before and after surgery nearly doubled the time patients with early-stage lung cancer lived without their disease returning, according to final results from the Phase 3 IMpower030 trial presented on September 12 at…

Imfinzi-Imdelltra combo shows major survival gain in small cell lung cancer

AstraZeneca and Amgen on Tuesday announced that a combination of Imfinzi (durvalumab) and Imdelltra (tarlatamab) delivered a statistically significant improvement in overall survival compared to Imfinzi alone as first-line maintenance therapy for extensive-stage small cell lung cancer, a disease in…

Ivonescimab tops Keytruda in overall survival for first time in lung cancer trial

Akeso and Summit Therapeutics announced on September 2 that their bispecific antibody ivonescimab achieved a statistically significant overall survival improvement over Merck's blockbuster Keytruda in a Phase 3 trial treating PD-L1-positive non-small cell lung cancer, marking the first time a…

Enhertu tops standard care in first-line HER2 lung cancer trial

AstraZeneca and Daiichi Sankyo announced on Monday that their antibody drug conjugate Enhertu demonstrated a statistically significant improvement in progression-free survival over the current global standard of care as a first-line treatment for patients with HER2-mutant advanced lung cancer, marking…

Nature Medicine retracts lung cancer study on morning immunotherapy

Nature Medicine Springer Nature Group on Tuesday retracted a phase 3 clinical trial that reported patients with advanced lung cancer who received immunotherapy before 3 p.m. lived nearly a year longer than those treated later in the day — removing…